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Indoleamine 2,3-dioxygenase
KynurenineIndoleamine 2,3-dioxygenase (IDO), an enzyme that is ubiquitously distributed in mammalian tissues and cells,
converts tryptophan to kynurenine, and is also known as a keymolecule that promotes apoptosis in lymphocytes
and neurons. In this study, we established hepatitis B virus (HBV)-transgenic (Tg)/IDO-knockout (KO) mice
and examined the inﬂuence of IDO in a murine fulminant hepatitis model induced by HBV-speciﬁc cytotoxic
T lymphocytes (CTL). An increase of IDO expression in the livers of HBV-Tg/IDO-wild-type (WT) mice
administered HBV-speciﬁc CTL was conﬁrmed by real-time polymerase chain reaction, western blotting,
and evaluating IDO activity. Plasma alanine aminotransferase (ALT) levels in HBV-Tg/IDO-KO mice after
HBV-speciﬁc CTL injection signiﬁcantly decreased compared with those in HBV-Tg/IDO-WT mice. An inhibitor
of IDO, 1-methyl-D-tryptophan (1-MT), could also attenuated the observed liver injury induced by this
HBV-speciﬁc CTL. The expression levels of cytokine and chemokine mRNAs in the livers of HBV-Tg/IDO-WT
mice were higher than those in the livers of HBV-Tg/IDO-KOmice. The administration of kynurenine aggravated
the liver injury in HBV-Tg/IDO-KO mice injected with HBV-speciﬁc CTL. Simultaneous injection of recombinant
murine interferon (IFN-γ) and kynurenine also increased the ALT levels in HBV-Tg/IDO-KOmice. The liver injury
induced by IFN-γ and kynurenine was improved in HBV-Tg/tumor necrosis factor-α-KO mice. Conclusion:
Kynurenine and IFN-γ induced by the administration with HBV-speciﬁc CTL are cooperatively involved in the
progression of liver injury in acute hepatitis model. Our results may lead to a new therapy for the acute liver in-
jury caused by HBV infection.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Fulminant hepatitis is a severe, rapidly progressive loss of hepatic
function due to viral infection or other cause of inﬂammatory
destruction of liver tissue [1]. Hepatitis B virus (HBV) infection can
cause fulminant hepatitis; this disease has a high mortality rate de-
spite intensive medical care and the implementation of the latest
therapies, including liver transplantation. HBV is a non-lytic virus
that does not cause direct cell damage [2]. Liver damage and viral
clearance after HBV infection are thought to be mediated by the
host cellular immune response to viral antigens. A fulminant hepatitis
model has been examined in mice by using adoptive transfer of HBV-
speciﬁc cytotoxic T lymphocytes (CTL) into HBV-transgenic (Tg) mice
[3–5]. The mice develop a necroinﬂammatory liver disease that is
histologically similar to acute viral hepatitis in humans. Various studies81 58 230 6431.have been performed on viral clearance and liver diseases in HBV infec-
tion by using this murine fulminant hepatitis model [4,6,7].
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is ubiquitous-
ly distributed in mammalian tissues and cells; this enzyme converts
tryptophan to N-formylkynurenine, which is further catabolized to
kynurenine. IDO is induced via an IFN-γ dependent and/or an indepen-
dent mechanism as well as other pro-inﬂammatory cytokines in the
course of an inﬂammatory response in various cell types, including
macrophages, ﬁbroblasts, and epithelial cells [8,9]. Previously, we re-
ported that IDO expression in hepatocytes is increased after HBV-
speciﬁc CTL injection into HBV-Tgmice [7]. In thismodel, IFN-γ induced
by the CTL injection was involved in the observed increase in the IDO
expression on the liver, which is also reportedly up-regulated in hepati-
tis virus-infected woodchuck [10]. Thus, IDO expression in the liver is
strongly increased in acute and fulminant viral hepatitis. Kynurenine
and other tryptophan metabolites produced by IDO promote cell
death and tissue injury [11]. On the other hand, immune-mediated
diseases such as GVHD are improved by the activation of IDO [12].
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jury. The role of increased IDO expression is not deﬁned clearly in the
fulminant hepatitis model induced by HBV-speciﬁc CTL. In the pres-
ent study, we established HBV-Tg/IDO-KO mice and examined the
inﬂuence of induced IDO during acute liver injury caused by HBV-
speciﬁc CTL.
2. Material and methods
2.1. Reagents
1-Methyl-D-tryptophan (1-MT) and L-kynurenine were purchased
from Sigma-Aldrich (St. Louis, MO). Recombinant murine IFN-γ was
purchased from Peprotech (Rocky Hill, NJ).
2.2. Mice
The HBV-Tg mouse lineage 107-5D (ofﬁcial designation Tg [Alb-1,
HBV] Bri66; inbred B10.D2, H-2d), in which the HBV envelope coding
region is under the control of themouse albumin promoter, was provid-
ed by Dr. F. V. Chisari (Department of Molecular and Experimental
Medicine, Scripps Research Institute, La Jolla, CA). IDO1 gene knockout
(IDO-KO) mice on a C57BL/6J background were obtained from
Jackson Laboratory (Bar Harbor, ME) and backcrossed to B10.D2
(H-2d). HBV-Tg/IDO-KO mice were produced by backcrossing IDO-KO
mice with 107-5D. TNF-α-KO mice were produced by gene targeting
as described previously [13] and backcrossed onto B10.D2 (H-2d).
HBV-Tg/TNF-α-KO mice were produced by backcrossing TNF-α-KO
micewith 107-5D. All animal procedureswere conducted in accordance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and guidelines for the care and use of animals
established by the Animal Care and Use Committee of Gifu University.
2.3. Cell lines
P815 cells expressingHBV-preS1, 2, andS (P815preS1)were provided
by Dr. F. V. Chisari. HBV-speciﬁc CD8+ CTL clones were produced as
described in a previous report [14]. The clones are H-2d restricted, and
can recognize an epitope (IPQSLDSWWTSL) located between residues
28 and 39 of the hepatitis B surface antigen (HBsAg). The CTL were
washed 5 d after a ﬁnal stimulation with irradiated P815preS1 and then
intravenously injected into HBV-Tg mice.
2.4. Fulminant hepatitis model and assessment of hepatocellular injury
HBV-speciﬁc CD8+ CTL clones (1 × 106/mouse) were intravenously
injected into HBV-Tg/IDO-WT, IDO-WT, HBV-Tg/IDO-KO, and IDO-KO
mice. To monitor hepatocellular injury, plasma alanine aminotransferase
(ALT) activity was measured using an automated clinical analyzer
BM2250 (JEOL, Tokyo, Japan).
2.5. Histological examination
Histopathological examination of the liver was performed at 0 d
and 2 d after CTL injection. The liver was ﬁxed with 10% formalin in
PBS for 48 h and then embedded in parafﬁn. Tissue sections were
deparafﬁnized, stained with hematoxylin and eosin, and examined
under light microscopy. TUNEL staining was performed using in situ
apoptosis detection kit (Takara Bio, Shiga, Japan), according to the
manufacturer's instructions. Necroinﬂammatory foci are deﬁned as the
existence of inﬂammatory cell inﬁltration and hepatocyte necrosis
more than three, and inﬂammatory cell foci are deﬁned as the existence
of inﬂammatory cell more than ten in parafﬁn sections of the liver. The
data are represented as the numerical value per area (1 mm2).2.6. Measurement of kynurenine
Kynurenine was measured using high-performance liquid chro-
matography (HPLC) equipped with a spectrophotometric detector
(Tosoh ultraviolet-8000, Tosoh, Tokyo, Japan) as described in a
previous study [8].2.7. Assay of IDO activity
IDO activity was assessed using the methylene blue/ascorbate assay, as
described previously [15]. Brieﬂy, the liver lysate was centrifuged at 7000
×g at 4 °C for 10 min. The supernatant (50 μL) was then reacted with the
substrate solution (50 μL) at 37 °C for 60 min. The substrate solution
comprised 100 mM potassium phosphate buffer (pH 6.5), 50 μM
methylene blue, 20 μg of catalase, 50 mM ascorbate and 0.4 mM
D-tryptophan. After incubation, the samples were acidiﬁed with
3% perchloric acid and centrifuged at 7000 ×g at 4 °C for 10 min.
The concentration of kynurenine in the supernatant of the reaction
solution was measured using HPLC, and IDO activity was expressed
as the kynurenine content per hour per milligram protein.2.8. Real-time RT-PCR analysis
Real-time reverse transcription polymerase chain reaction (RT-PCR)
was used to quantify the levels of TNF-α, IFN-γ, IL-6, IL-10, MCP-1,
and MIP-2 mRNA in the liver. Total RNA in the liver was isolated using
Isogen (Nippon Gene, Tokyo, Japan) and reverse-transcribed to cDNA
by using a High capacity cDNA transcription kit (Applied Biosystems,
Foster City, CA). Puriﬁed cDNA was used as the template for real-time
RT-PCR conducted with pre-designed primer/probe sets for TNF-α,
IFN-γ, IL-6, IL-10, MCP-1, MIP-2 mRNA and 18S rRNA (Applied
Biosystems), according to the manufacturer's recommendations.
18S rRNA was used as an internal control. Real-time RT-PCR was car-
ried out using a Light-Cycler 480 system (Roche Diagnostic Systems).2.9. Western blot analysis
Protein (40 μg) from the liver lysate was subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then trans-
ferred to a nitrocellulose membrane. The membrane was blocked with
5% skim milk and incubated with anti-IDO and anti-β-actin antibodies
for 24 h at 4 °C, followed by incubation with peroxidase-labeled anti-
rabbit IgG for 60 min at room temperature. Immunoreactive protein
bands were visualized using ECL plus (GE Healthcare UK Ltd, England).2.10. Isolation of liver mononuclear cells and ﬂow cytometry analysis
Hepatic mononuclear cells (MNCs) were isolated as outlined in our
previous report [16]. Brieﬂy, the mouse liver tissue was minced using
a pair of scissors and the resultant liver homogenate was ﬁltered
through a stainless steel mesh. MNCs were obtained by the centrifuga-
tion of liver homogenate with Ficoll-Conray (IBL, Gunma, Japan). Flow
cytometry was used to evaluate the cell phenotypes in the liver MNCs
at 0 h and 24 h after CTL injection. The MNCs were then stained with
below-mentioned antibodies: FITC-conjugated hamster anti-mouse
CD3ε antibody (clone 145-2C11; BD Biosciences, Franklin Lakes, NJ),
FITC-conjugated rat anti-mouse CD4 antibody (clone RM4-5; BD
Biosciences), PE-conjugated rat anti-mouse CD8 antibody (clone 53-6.7;
BD Biosciences), CD49b PE-conjugated rat anti-mouse CD49b antibody
(clone DX5; BD Biosciences) and FITC-conjugated rat anti-mouse F4/80
antibody (clone BM8; eBioscience, San Diego, CA). The phenotypic
characterization of the MNCs was carried out using a FACScan ﬂow
cytometer (BD Biosciences).
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Plasma HBsAg level was measured using an automated clinical
analyzer HISCL 2000i and mouse anti-HBsAg antibody (Sysmex,
Kobe, Japan) according to the manufacturer's recommendations.2.12. Statistical analysis
In each experiment, the results are expressed as mean ± SD. The
statistical signiﬁcance of the difference in mean values was determined
using Student's t test, and p values less than 0.05 were considered
statistically signiﬁcant.3. Results
3.1. Up-regulation of IDO expression in the mouse liver following injection
of HBV-speciﬁc CTL
HBV-speciﬁc CTL clones (1 × 106/mouse) were intravenously
injected into HBV-Tg/IDO-WT and HBV-Tg/IDO-KO mice. The ex-
pression of IDO mRNA in the livers from HBV-Tg/IDO-WT mice
was markedly up-regulated mainly at 2 d after CTL injection,
whereas that from HBV-Tg/IDO-KO mice was not detected by
real-time RT-PCR (Fig. 1A). The IDO protein and activity in the
liver tissue from HBV-Tg/IDO-WT mice were also increased 2 d
after CTL injection (Fig. 1B, C). Plasma kynurenine concentrations
in HBV-Tg/IDO-WT mice were signiﬁcantly increased relative
to those in HBV-Tg/IDO-KO mice at 1 d, 2 d, 4 d, and 7 d after
CTL injection (Fig. 1D). These data suggest that IDO expression in
the liver was induced after CTL injection, resulting in increased
kynurenine production.A
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each group. *, p b 0.05.3.2. Effects of IDO on liver damage induced by HBV-speciﬁc CTL
Plasma ALT levels in HBV-Tg/IDO-KO mice at 1 d and 2 d after
CTL injection signiﬁcantly decreased compared with the levels in
HBV-Tg/IDO-WT mice (Fig. 2A). Histological changes were ob-
served in the liver tissues from HBV Tg/IDO-WT and HBV-Tg/IDO-KO
mice at 0 d and 2 d after CTL injection. The number of inﬁltrating cells
and necroinﬂammatory foci in the livers of HBV Tg/IDO-KO mice 2 d after
CTL injection was much less than that in the livers of HBV-Tg/IDO-WT
mice (Fig. 2B). Moreover, as evaluated by TUNEL staining, a large number
of apoptotic hepatocytes were detected in the livers of HBV-Tg/IDO-WT
mice at 2 d after CTL injection compared to those found in the livers of
HBV-Tg/IDO-KOmice (Fig. 2C).
3.3. Effect of IDO on cytokine and chemokine expression inmouse liver after
injection of HBV-speciﬁc CTL
Cytokine (TNF-α, IFN-γ, IL-6, IL-10) and chemokine (MCP-1, MIP-2)
mRNA expression was determined in the livers of HBV-Tg/IDO-WT and
HBV Tg/IDO-KO mice at 0 d, 1 d, 2 d and 7 d following CTL injection.
The mRNA expression of TNF-α, IFN-γ, IL-6, MCP-1 and MIP-2
examined in the livers from HBV-Tg/IDO-KO mice was decreased
relative to those from the HBV-Tg/IDO-WTmice (Fig. 3A). Additionally,
cytokine (TNF-α, IFN-γ) mRNA expression was up-regulated in non-
parenchymal cells after CTL injection (Fig. 3B), but there was no signif-
icant difference between HBV-Tg/IDO-WT mice and HBV-Tg/IDO-KO
mice in cytokine mRNA expression of non-parenchymal cells (Fig. 3B).
3.4. Effect of IDO on the phenotype of MNCs in the liver after injection of
HBV-speciﬁc CTL
Next, we examined the phenotypes of the MNCs in the livers (CD4+,
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injection. The total number ofMNCs in the livers of HBV-Tg/IDO-WTmice
and HBV-Tg/IDO-KO mice was increased at 24 h after CTL injection. The
increase in cell number was more reduced in HBV-Tg/IDO-KO mice
compared with HBV-Tg/IDO-WTmice. Although there was no signiﬁcant
difference between HBV-Tg/IDO-WT and HBV-Tg/IDO-KO with regard
to the number of CD4+, CD8+, CD3+CD49b−, CD3−CD49b+, and
CD3+CD49b+ cells at 0 d and 24 h after CTL injection, F4/80+ cells in
HBV-Tg/IDO-KO mice signiﬁcantly decreased compared to those in
HBV-Tg/IDO-WT mice at 24 h after the CTL injection (Table 1).
3.5. Effects of 1-MT treatment or kynurenine on liver damage induced by
HBV-speciﬁc CTL
Because the liver damage in HBV-Tg/IDO-KO mice improved in
comparisonwith that in HBV-Tg/IDO-WTmice,we evaluated the effectsof 1-MT, a potent inhibitor of IDO, on liver damage. HBV-Tg/IDO-WT
mice were orally administered 1-MT (5 mg/mL) in drinking water for
3 d prior to CTL injection. The plasma ALT levels in HBV-Tg/IDO-WT
mice that received 1-MT were signiﬁcantly decreased compared to
HBV-Tg/IDO-WT mice that did not receive 1-MT at 1 d, 2 d and 4 d
after CTL injection (Fig. 4A). The number of necroinﬂammatory foci in
the liver of HBV-Tg/IDO-WT mice administered 1-MT at 2 d after CTL
injection was lesser than that in the livers of HBV-Tg/IDO-WT mice
that were not administered 1-MT, whereas there was no signiﬁcant
difference in inﬂammatory cell foci with or without the 1-MT
administration (Fig. 4B).
HBV-Tg/IDO-KOmicewere intraperitoneally administered kynurenine
(50 mg·kg−1·day−1) in 0.2 mL of PBS for 7 d after the CTL injection.
The plasma ALT level in HBV-Tg/IDO-KO mice that were adminis-
tered kynurenine was signiﬁcantly increased compared to that
in HBV-Tg/IDO-KO mice that were not administered kynurenine
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necroinﬂammatory foci in the liver of HBV-Tg/IDO-KO mice adminis-
tered kynurenine at 2 days after the CTL injection was signiﬁcantly
increased compared with those in the liver of HBV-Tg/IDO-KO mice
not administered kynurenine, but no signiﬁcant difference was not
conﬁrmed in the inﬂammatory cell foci with or without the kynurenine
administration (Fig. 4D).3.6. Effect of IDO on circulating HBsAg after injection of HBV-speciﬁc CTL
HBsAg expression in HBV-Tg mice may affect the liver damage after
CTL injection. Therefore, we next examined plasma HBsAg levels in
HBV-Tg/IDO-WT mice and HBV-Tg/IDO-KO mice after CTL injection.
There was no difference among HBV-Tg/IDO-WT mice, HBV-Tg/IDO-
KO mice and HBV-Tg/IDO-WT mice in plasma HBsAg levels after CTLTable 1
The cell number of the MNCs in the livers of HBV-Tg/IDO-WT and HBV-Tg/IDO-KO mice follow
Day 0
HBV-Tg/IDO-WT HBV-T
Total cell number (×104) 18.0 ± 2.2 19.3 ±
F4/80+ (×104) 2.6 ± 0.9 2.3 ±
CD4+ (×104) 3.9 ± 1.0 4.5 ±
CD8+ (×104) 1.3 ± 0.3 1.7 ±
CD3+CD49b− (×104) 3.4 ± 0.6 3.8 ±
CD3−CD49b+ (×104) 3.3 ± 0.7 3.0 ±
CD3+CD49b+ (×104) 0.8 ± 0.2 0.9 ±
Means following the superscript * showed signiﬁcant differences at p b 0.05.injection (Fig. 5). It was conﬁrmed that HBsAg was not detected in
plasma from non-HBV-Tg mice (data not shown).
3.7. Effect of kynurenine treatment on liver damage and TNF-α mRNA
expression induced by recombinant IFN-γ
HBV-Tg/IDO-KO mice were intraperitoneally injected with
L-kynurenine (50 mg·kg−1·day−1) in 0.2 mL PBS for 2 d after receiv-
ing a recombinant IFN-γ injection. PlasmaALT levels in HBV-Tg/IDO-KO
mice that were administered L-kynurenine were signiﬁcantly increased
compared to those in HBV-Tg/IDO-KOmice that were not administered
kynurenine at 2 d after the recombinant IFN-γ injection (Fig. 6A).
Moreover, ALT levels in HBV-Tg/TNF-α-KO mice that were adminis-
tered L-kynurenine and recombinant IFN-γ were decreased com-
pared to those in HBV-Tg/IDO-KO mice. These data indicated that
co-administration of L-kynurenine and recombinant IFN-γ induceding HBV-speciﬁc CTL injection.
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Fig. 4. The effect of 1-MT and kynurenine on liver injury induced by HBV-speciﬁc CTL inHBV-Tgmice. (A, B)HBV-Tg/IDO-WTmicewere orally administered 1-MT at 0 mg/mL or 5 mg/mL
in drinkingwater for 3 d prior to HBV-speciﬁc CTL injection. Plasma ALT levelswere analyzed at 0 d, 1 d, 2 d, 4 d, and 7 d after CTL injection. Hematoxylin and eosin stainingwas performed
inmouse liver tissues at 2 d after CTL injection. (C, D)HBV-Tg/IDO-KOmicewere injectedwithHBV-speciﬁc CTL followedby intraperitoneal injectionwith kynurenine (KYN) daily. Plasma
ALT levels were analyzed at 0 d, 1 d, 2 d, 4 d, and 7 d after CTL injection (A, C). Hematoxylin and eosin staining was performed in liver tissues at 2 d after CTL injection (B, D). Data are
represented as mean ± SD of the results from 4 to 6 mice in each group. *, p b 0.05.
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mRNA expression was signiﬁcantly up-regulated by recombinant
IFN-γ injection in the liver from HBV-Tg/IDO-KO mice, but L-kynurenine
administration had no inﬂuence on the TNF-αmRNA expression in the
liver without IFN-γ injection (Fig. 6B).A
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4. Discussion
HBV is a DNA virus that is known to infect and cause disease in
humans. Infection with HBV is a serious worldwide health problem
resulting in fulminant hepatitis, a clinical syndrome consisting of sud-
den and severe liver injury that leads to hepatic encephalopathy and
acute liver failure [1,17,18]. The mortality rate attributed to fulminant0
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Fig. 5. Effect of IDO on circulating HBsAg after injection with HBV-speciﬁc CTL. Plasma
HBsAg levels after CTL injection in HBV-Tg/IDO-WT mice with or without 1-MT and
HBV-Tg/IDO-KO mice were measured. Data are represented as mean ± SD of the results
from 3 to 4 mice in each group.hepatitis is approximately 40%. The HBV-Tg mouse model has been
useful for deﬁning mechanisms associated with the development
of fulminant hepatitis [3–5]. This same mouse model enabled us toB
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Fig. 6. The effect of recombinant IFN-γ in HBV-Tg mice. (A) HBV-Tg/IDO-KO or HBV-
Tg/TNF-α-KO mice were intravenously administered recombinant murine IFN-γ
followed by intraperitoneal injections of KYN, and plasma ALT levels in those mice
were measured. (B) IFN-γ induced TNF-α mRNA expression in HBV-Tg/IDO-KO
with or without KYN treatment was measured. Data are represented as mean ± SD
of the results from 3 to 6 mice in each group. *, p b 0.05.
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nant hepatitis as well as to evaluate drug therapies for curing HBV
infection. Previously, we had reported that the IDO expression in
the hepatocytes was increased in the murine fulminant hepatitis
model [7]. IFN-γ induced by HBV-speciﬁc CTL enhances the expres-
sion of IDO in HBV-Tg mouse hepatocytes. However, the role of
enhanced hepatocyte IDO expression following HBV-speciﬁc CTL
injection is unclear. In this study, we have established an HBV-
Tg/IDO-KOmouse strain and evaluated the effects of IDO on liver injury
induced by HBV-speciﬁc CTL.
IDO is an enzyme that catabolizes tryptophan via the kynurenine
pathway to form nicotinic acid, niacin, and nicotinamide adenine
dinucleotides. IDO is induced by proinﬂammatory cytokines, including
IFN-γ. Furthermore, IDO is expressed in human and mouse tumor
cells, DCs, and macrophages following microbial or viral infections. We
recently demonstrated that IDO is induced in the hepatocytes of mice
injected with α-galactosylceramide which has an agonistic effect on
natural killer T (NKT) cells [19]. Moreover, hepatocyte IDO expres-
sion was increased after HBV-speciﬁc CTL was administered to the
HBV Tg mouse [7]. In the fulminant hepatitis model used in this previ-
ous study, IFN-γ directly up-regulated the hepatocyte IDO expression.
In our present study, IDO expression was similarly increased in the
livers of HBV-Tg/IDO-WTmice following CTL injection, and IDO activity
was up-regulated in the liver (Fig. 1). Plasma kynurenine level in HBV-
Tg/IDO-WT mice also increased after CTL injection. On the other hand,
the expression of IDO mRNA in the liver and plasma kynurenine level
were not enhanced by CTL injection in HBV-Tg/IDO-WT mice. Our cur-
rent data demonstrate that IDO deﬁciency in the HBV-Tg mice can at-
tenuate liver injury after HBV-speciﬁc CTL injection (Fig. 2A and B).
Additionally, the number of apoptotic hepatocytes decreased in HBV-
Tg/IDO-KO mice compared to HBV-Tg/IDO-WT mice (Fig. 2C). Recent
study demonstrated that the enhancement of IDO activity inhibited
HBV replication in vitro [20]. HBsAg expression affects liver injury in-
duced by HBV-speciﬁc CTL in HBV-Tg mice. In the present model,
HBsAg expression was not affected by the suppression of IDO activity
in mice after CTL injection (Fig. 5). Therefore, the difference between
HBV Tg/WT and HBV Tg/IDO-KOmice in liver injury was not dependent
on HBsAg expression in these mice. Real time RT-PCR experiments re-
vealed that the mRNA expression of proinﬂammatory cytokines and
chemokines was decreased in HBV-Tg/IDO-KO mice relative to the
HBV-Tg/IDO-WT mice (Fig. 3A). These cytokine expressions were en-
hanced in non-parenchymal cells but not in hepatocytes. However,
there was no signiﬁcant difference in TNF-α and IFN-γmRNA expres-
sion after CTL injection between HBV-Tg/IDO-WT and HBV-Tg/IDO-
KO mice (Fig. 3B). The difference in inﬁltrating cell number be-
tween HBV-Tg/IDO-WT and HBV-Tg/IDO-KO mice contributes to the
difference in inﬂammatory cytokine expression in the whole liver
(Table 1). The reduction on the expression of these cytokines and
chemokines in the liver indicated that the inﬂammation in the liver of
HBV-Tg/IDO-KO mice administered CTL was decreased. In general, in-
creased hepatic IDO expression induces apoptosis in activated T cells
and NK cells [21]. Our previous report has also shown that the number
of activated lymphocytes in WTmice is obviously decreased compared
to those in IDO-KO mice in α-galactosylceramide-induced hepatitis
model [19]. Several studies have shown that tryptophan metabolites
can induce apoptosis in some kinds of cells in vitro and in vivo
[21–23]. IDO exerts an immunosuppressive effect via the induction of
apoptosis in T cells and NK cells. Moreover, tryptophanmetabolites (in-
cluding kynurenine, 3-hydroxy-kynurenine, 3-hydroxyanthranilic acid,
and quinolinic acid) produced by IDO catalysis have neurotoxic effects
[24,25]. Our current data also indicate that tryptophan metabolites, in
particular kynurenine, can aggravate liver injury in HBV-Tg mice fol-
lowing HBV-speciﬁc CTL injection (Fig. 4C, D). However, administering
kynurenine alone did not promote liver injury in the HBV-Tg mice
(Fig. 4C and D). HBV-speciﬁc CTL injection was also required to induce
the observed hepatotoxicity caused by kynurenine in HBV-Tg mice.In this hepatitis model, the increase of IFN-γ production after HBV-
speciﬁc CTL injection is required for the progression of liver injury.
Our results strongly suggested that IFN-γ in cooperation with
kynurenine is involved in liver injury induced by HBV-speciﬁc CTL.
Previously our study demonstrated that TNF-α also deeply contrib-
utes to liver injury promoted by HBV-speciﬁc CTL [7]. The progres-
sion of liver injury depended on the TNF-α produced by non-HBsAg-
speciﬁc inﬂammatory cells stimulated with IFN-γ. TNFR1 expression
in hepatocytes was up-regulated after HBV-speciﬁc CTL injection, and
it was considered that hepatocytes became more susceptible to TNF-α
after CTL injection [4]. Therefore, the effect of the administration with
IFN-γ and kynurenine was examined in HBV-Tg/TNF-α-KO mice. The
liver injury induced byHBV-speciﬁc CTL in HBV-Tg/TNF-α-KOmice sig-
niﬁcantly improved compared to that in HBV-Tg/IDO-KOmice (Fig. 6A).
These data suggested that TNF-α is also involved in IFN-γ and
kynurenine induced liver injury in HBV-Tg mice. Moreover, IFN-γ in-
creased the expression of TNF-α with or without kynurenine in HBV-
Tg/IDO-KO mice (Fig. 6B). We suspected that the cooperative effect of
TNF-α from non-HBsAg-speciﬁc inﬂammatory cells stimulated with
IFN-γ and the increase of kynurenine in the liver are critical on the ac-
complishment of acute liver injury. Recent report demonstrated that
the livers of HBV-Tgmice are susceptible to liver injury by some cyto-
kines (IFN-γ and TNF-α) because of the accumulation of HBV anti-
gens [26]. Therefore, IDO activity and expression should be
suppressed in viral hepatitis to reduce liver injury. Our present re-
sults suggest that 1-MT can reduce liver injury in HBV-Tg mice ad-
ministered HBV-speciﬁc CTL (Fig. 4A and B). 1-MT may be available
in clinical therapy for severe acute hepatitis caused by HBV infection.
5. Conclusion
In conclusion, we have found that IDO deﬁciency attenuated liver
injury in HBV-Tg mice injected with HBV-speciﬁc CTL, which caused
HBV-speciﬁc CTL and other immune cells in the liver to secrete a large
amount of IFN-γ. Hepatocytes with accumulated HBV antigen are
susceptible to apoptosis in the simultaneous presence of both IFN-γ
and kynurenine. The observed reduction in IDO activity following
1-MT treatment could facilitate the development of effective therapies
for patients with fulminant hepatitis caused by HBV infection.
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